No Data
Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Somewhat Strained Balance Sheet
Zhejiang Huahai Pharmaceutical (600521.SH) will adjust the scale of the additional funds raised to not exceed 0.6 billion yuan.
Zhejiang Huahai Pharmaceutical (600521.SH) issued a notice, according to the relevant laws, regulations and normative documents, in conjunction with...
Huahai Pharma Gets Registration Certificate for Olmesartan Medoxomil Tablets
Zhejiang Huahai Pharmaceutical (600521.SH): Amlodipine besylate tablets have obtained the pharmaceutical registration certificate.
Gelonghui, February 7 - Zhejiang Huahai Pharmaceutical (600521.SH) announced that it recently received the "Pharmaceutical Registration Certificate" for Olmesartan Medoxomil Tablets approved by the National Medical Products Administration. Olmesartan Medoxomil Tablets are primarily used for the treatment of hypertension.
Zhejiang Huahai Pharmaceutical Gets US FDA Approval for Doxycycline Capsules
Zhejiang Huahai Pharmaceutical Subsidiary Gets Clinical Trial Approval for HB0017 New Indication
Earnings Are Growing at Zhejiang Huahai Pharmaceutical (SHSE:600521) but Shareholders Still Don't Like Its Prospects
